News

Dr. Califf Is Confirmed as FDA Commissioner; NORD Issues Statement


 

References

Following the confirmation by the U.S. Senate of Robert Califf, MD, as Commissioner of the Food and Drug Administration (FDA), NORD President and CEO Peter L. Saltonstall issued the following statement:

“On behalf of the rare disease community, I want to congratulate Dr. Califf on being confirmed as Commissioner of the FDA. Dr. Califf has spoken to NORD in the past and is familiar with the special issues facing our community. We look forward to working with him closely in the future.”

Prior to joining FDA in February 2015, Dr. Califf was Professor of Medicine and Vice Chancellor for clinical and translational research at Duke University. He is an internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research.

Recommended Reading

New Study Identifies Class of Drugs That Removes Abnormal Proteins in Brain and Improves Memory in Mice
MDedge Neurology
Global CNS Gene Therapy Clinical Trial Is Underway at NIH
MDedge Neurology
Mavoglurant disappoints in fragile X trials
MDedge Neurology
Dravet Syndrome Incidence Is Twice That of Prior Estimate
MDedge Neurology
Human gene editing consensus study underway
MDedge Neurology
Elevated cardiovascular risks linked to hidradenitis suppurativa
MDedge Neurology
COMMENTARY—Another Candidate for Diagnosing Myasthenia Gravis
MDedge Neurology
Test Accurately Diagnoses Myasthenia Gravis
MDedge Neurology
Brazilian study identifies fetal abnormalities linked to Zika virus
MDedge Neurology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Neurology